Table 1.
Clinical, radiological, and CSF data at first episode of LETM
| Demographic data | Whole cohort | Non-relapsing patients in the first 18 months | Relapsing patients in the first 18 months |
|---|---|---|---|
| n | 53 | 41 | 12 |
| Female, n (%) | 28 (52.8) | 22 (54%) | 6 (50%) |
| Age at onset, years median (range) | 38 (16.5–80) | 38 (16.5–80) | 43.2 (26–65) |
| Follow-up, years median (range) | 3.94 (1.5–12) | 2.88 (1.5–11.3) | 5.98 (3.91–12) |
| EDSS at nadir, median (range) | 6 (1–8.5) | 6.5 (1–8.5) | 5.25 (1–8.5) |
| Spinal cord MRI dataa | |||
| · Cervical only | 7 | 6 | 1 |
| · Thoracic only | 18 | 14 | 4 |
| · Lumbar only | 3 | 3 | 0 |
| · Cervical and thoracic | 14 | 10 | 4 |
| · Cervical, thoracic and lumbar | 7 | 6 | 1 |
| · Thoracic and lumbar | 4 | 2 | 2 |
| · Cervical involvement, n (%) | 28 (53%) | 22 (54%) | 6 (50%) |
| · Thoracic involvement, n (%) | 43 (81%) | 32 (78%) | 11 (92%) |
| · Lumbar involvement, n (%) | 14 (26%) | 11 (27%) | 3 (25%) |
| Laboratory datab | |||
| CSF OCB, n = 50, n (%) | 15 (30%) | 12/38 (32%) | 3/12 (25%) |
| CSF pleocytosis (> 5 cells/mm3), n = 52, n (%) | 28 (54%) | 22/40 (55%) | 6/12 (50%) |
| Proteinorachy (> 0.5 g/L), n = 51, n (%) | 24 (47%) | 18/39 (46%) | 6/12 (50%) |
LETM longitudinal extensive transverse myelitis, y years, m months, EDSS Expanded Disability Status Scale, CSF cerebrospinal fluid, OCB oligoclonal bands
aSpinal cord MRI performed in the first month after symptoms onset
bLumbar puncture performed during the first episode of LETM